These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20383503)

  • 1. Extramedullary manifestations of multiple myeloma in the thyroid gland and in the lungs: excellent response to therapy.
    Weisser F; Reuter C; Taverna C
    Ann Hematol; 2010 Nov; 89(11):1183-4. PubMed ID: 20383503
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
    Sher T; Miller KC; Lee K; Chanan-Khan A
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
    Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
    Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drugs for the treatment of multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Haematologica; 2010 May; 95(5):702-4. PubMed ID: 20442442
    [No Abstract]   [Full Text] [Related]  

  • 6. [Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma].
    Hanamura I; Iida S
    Gan To Kagaku Ryoho; 2010 May; 37(5):816-21. PubMed ID: 20524255
    [No Abstract]   [Full Text] [Related]  

  • 7. [Solitary and extramedullary plasmocytoma in the head and neck region: five cases report].
    Nasr Ben Ammar C; Ghorbel I; Kochbati L; Gargouri W; Touati S; Maalej M
    Cancer Radiother; 2010 Dec; 14(8):755-8. PubMed ID: 20673736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
    Candoni A; Simeone E; Fanin R
    Am J Hematol; 2008 Aug; 83(8):680-1. PubMed ID: 18459108
    [No Abstract]   [Full Text] [Related]  

  • 9. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
    Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
    Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
    [No Abstract]   [Full Text] [Related]  

  • 10. Thalidomide as initial therapy for early-stage myeloma.
    Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary involvement: an emerging problem in multiple myeloma.
    Molica S
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma and renal cell carcinoma possible association.
    Badros A; Karakunnel J; Dawson N
    Leuk Lymphoma; 2007 Aug; 48(8):1662-4. PubMed ID: 17701606
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
    Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extramedullary plasmacytomas in the context of multiple myeloma.
    Aguado B; Iñigo B; Sastre JL; Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():7-13. PubMed ID: 22105528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pomalidomide in the treatment of multiple myeloma - own experience and overview of literature].
    Adam Z; Pour L; Krejčí M; Vetešníková E; Sandecká V; Štork M; Čermáková Z; Pourová E; Ševčíková S; Král Z; Mayer J
    Vnitr Lek; 2016; 62(12):962-968. PubMed ID: 28139124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple myeloma with unusual intracranial manifestations.
    Konick L; Hafez GR; Weiss SL; Oberley TD; Hartmann HA
    Arch Pathol Lab Med; 1986 Aug; 110(8):755-6. PubMed ID: 3755331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
    Terrier B; Aouba A; Diop S; Clerc J; Vasiliu V; Munera Y; Hermine O
    Leuk Lymphoma; 2006 Jul; 47(7):1424-6. PubMed ID: 16923585
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
    Nakazato T; Mihara A; Ito C; Sanada Y; Aisa Y
    Ann Hematol; 2012 Mar; 91(3):473-4. PubMed ID: 21647581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.